Introduction: Activation of the fibroblast growth factor receptor (FGFR) family through fusion with various partners has been described in multiple cancer types, including NSCLC. FGFR inhibitors are currently being evaluated clinically for patients whose tumors harbor these fusions.
Results: FGFR fusions retaining the kinase domain were identified in 0.2% of NSCLC cases; they included 37 fibroblast growth factor receptor gene 3 (FGFR3)-transforming acidic coiled-coil containing protein 3 gene (TACC3) fusionpositive cases, two fibroblast growth factor receptor 2 (FGFR2)-shootin 1 gene (KIAA1598 [also known as SHTN1]) fusion-positive cases, one BCL2 associated athanogene 4 gene (BAG4)-fibroblast growth factor receptor 1 gene (FGFR1) fusion-positive case, and 12 novel FGFR1, FGFR2, FGFR3, and fibroblast growth factor receptor 4 gene (FGFR4) fusion-positive cases. Co-occurring EGFR or MNNG HOS Transforming gene (MET) alterations were observed in 8% of cases (four of 52), KRAS mutation was observed in three additional cases, and FGFR1 or FGFR3 amplification was observed in 10% of cases. The two patients with cooccurring EGFR mutations were previously treated with EGFR inhibitors. One patient with a novel FGFR2-leucine zipper transcription factor like 1 gene (LZTFL1) fusion had a partial response to the pan-FGFR inhibitor JNJ-42756493 and remained progression-free for 11 months.
Conclusion: FGFR fusions were detected by using comprehensive genomic profiling in 0.2% of NSCLCs; they occurred primarily in the absence of other known driver alterations, or in a subset of cases, as likely mechanisms of acquired resistance. One patient with a novel FGFR2 fusion had clinical benefit from an investigational FGFR inhibitor, suggesting that these alterations may predict response to targeted therapies.
Introduction
Advances in sequencing technology have enabled comprehensive genomic analyses of NSCLC, including squamous cell carcinoma (SCC), 1 adenocarcinoma, 2 and sarcomatoid carcinoma. 3 Although NSCLC was previously thought of as a relatively homogenous disease, we now understand that it comprises subsets of diseases driven by distinct molecular changes. Targeted agents *Corresponding author.
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against alterations in EGFR, ROS1, ALK receptor tyrosine kinase gene (ALK), and BRAF have resulted in impressive therapeutic responses and have become the standard frontline therapy for patients whose cancers harbor these mutations. [4] [5] [6] [7] [8] The fibroblast growth factor receptor (FGFR) is a family of four receptor tyrosine kinases (fibroblast growth factor receptor 1 gene [FGFR1], fibroblast growth factor receptor 2 gene [FGFR2], fibroblast growth factor receptor 3 gene [FGFR3], and fibroblast growth factor receptor 4 gene [FGFR4]) that when bound to their ligands, lead to the downstream activation of diverse pathways, including phospholipase Cg, mitogen-activated protein kinase, AKT, and signal transducer and activator of transcription. FGFRs play a key role in various cellular functions associated with proliferation and survival. 9 Alterations in FGFR have been reported in a multitude of solid malignancies, including lung, breast, urothelial, melanoma, cholangiocarcinoma, and prostate cancers. These alterations lead to dysregulation and include gain-of-function mutations, amplification, and formation of aberrant fusion proteins that allow for ligand-independent signaling. 10 The incidence of alterations in FGFR, especially amplification of FGFR1, has been reported to be higher in SCC of the lung than in adenocarcinoma (22% versus 3%).
11 FGFR1 amplifications are also seen more commonly in current smokers; in contrast, most targetable mutations have been found in patients with lung adenocarcinoma who are never-smokers or light former smokers. 11 Multikinase inhibitors with anti-FGFR activity, as well as specific pan-FGFR inhibitors, are in various stages of clinical development, and their efficacy is being evaluated in clinical trials. 12, 13 FGFR fusions are of particular interest, as preclinical work and emerging clinical data suggest that they convey sensitivity to FGFR inhibition. [14] [15] [16] In solid tumors, FGFR is frequently the 5' fusion partner, with the breakpoint found most frequently in introns or exons 17, 18, or 19, resulting in intact extracellular, transmembrane, and kinase domains. 17 The maintenance of the kinase domain has been shown to be critical to the function of the fusion protein. Almost all FGFR fusion partners contain a dimerization domain that allows for autophosphorylation and activation of FGFR signaling. 17 One of the most common fusion proteins is FGFR3-transforming acidic coiled-coil containing 3 (TACC3). Transforming acidic coiled-coil containing 3 gene (TACC3) encodes for a Cterminal coiled-coil domain. The fusion occurs by a tandem duplication event and results in activation of FGFR3 signaling. 18 The FGFR3-TACC3 fusion was first described in glioblastoma multiforme, 19 but has subsequently been detected in various tumor types. In NSCLC, however, although FGFR1 amplification has been defined in several data sets, diverse FGFR fusions have not been well described.
We reviewed the results of comprehensive genomic profiling (CGP) in 26,054 cases of NSCLC and examined the frequency and clinical characteristics of patients whose tumors harbor FGFR fusions. To our knowledge, this is the most in-depth evaluation of FGFR fusions exclusively in NSCLC. Here we will describe 52 NSCLC cases harboring 14 unique FGFR fusion pairs.
Methods
CGP utilizes next-generation sequencing to identify four major classes of alterations (base substitutions, insertions/deletions, copy number alterations, and rearrangements) across hundreds of genes implicated in cancer. As such, CGP is not limited to a particular cancer subset and can be used across malignancies. In the era of precision medicine, CGP has enabled the detection of alterations amenable to targeted therapy that were previously undetected by either single-marker or multigene hotspot testing.
The Foundation Medicine CGP platform was used in this analysis, with the second version of the assay updating the number of abnormalities evaluated per sample. In brief, at least 50 ng of DNA was extracted from formalin-fixed paraffin-embedded sections and CGP was performed on hybridization-captured, adaptor ligation-based libraries to a mean coverage depth of greater than 600Â for 235 (version 1) or 315 (version 2) cancer-related genes (including FGFR1, FGFR2, FGFR3, and FGFR4) plus select introns from 19 (version 1) or 28 (version 2) genes that are frequently rearranged in cancer, as previously described. 20 A minimum median coverage of more than 150Â was required for each sample, and at least 99% of baits (intron and exon) were required to have more than 100Â coverage. Sequencing coverage for FGFR1, FGFR2, FGFR3, and FGFR4 is detailed in Table 1 . Cases positive for FGFR1, FGFR2, FGFR3, and FGFR4 fusions retaining the kinase domain were identified. Additional FGFR rearrangements predicted to disrupt the kinase domain or rearrangements without identifiable fusion partners were excluded from this analysis. In all, samples from 26,054 consecutive NSCLC cases were submitted as part of routine care to Foundation Medicine (Cambridge, MA), which is a Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited reference laboratory, from May 2012 to September 2017. In this study, 3531 samples were evaluated with version 1 and 22,523 samples were evaluated with version 2. As part of the assay, tumor mutational burden (TMB) was also determined for each sample. TMB was calculated as the total number of relevant mutations divided by the coding region target territory of the test (0.83 megabases [Mb] for version 1 and 1.14 Mb for version 2) and is characterized as the number of somatic base substitutions or indel alterations per Mb after filtering to remove known somatic and deleterious mutations. 21, 22 Clinical data such as age, sex, histologic type, and stage were abstracted from reports accompanying each formalin-fixed, paraffin-embedded specimen. Ordinal relationships were examined by using the Mann-Whitney U test; categorical relationships were examined by using the Pearson chi-square test with Yates' continuity correction applied when applicable. Approval for this study, including a waiver of informed consent and a Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the Western Institutional Review Board (protocol No. 20152817).
Results

Clinical Characteristics
Of the 26,054 cases of NSCLC that were included, 17,827 (68%) were adenocarcinoma, 4037 (15%) were identified as NSCLC NOS (not otherwise specified), 3582 (14%) were SCC, 240 (0.9%) were sarcomatoid carcinoma, 216 (0.8%) were adenosquamous carcinoma, and 116 (0.4%) were large cell carcinoma. We identified 52 cases (0.2%) of NSCLC with FGFR fusions. In 48 cases FGFR was the 5' partner with canonical breakpoints in intron 17 or exon 18, with retention of the FGFR kinase domain. These included 37 cases with FGFR3-TACC3 fusions, two cases with FGFR2-shootin 1 gene (KIAA1598 [also known as SHTN1]) fusions, nine cases with eight novel FGFR2 fusions, and one case with a novel FGFR3 fusion. In four cases FGFR1, FGFR3, or FGFR4 was the 3' partner, with retention of the FGFR kinase domain. The median age of the 52 patients was 67.5 years (range 36-89) and 29 of 52 (56%) were male. In the FGFR fusionpositive cases, SCC and adenocarcinoma were the most common histologic types ( Table 2 .
Previously Described FGFR Fusions
Of our 52 FGFR fusion-positive cases, 37 harbored known activating FGFR3-TACC3 fusions, representing 15 unique variants (Table 2 and Fig. 1 ). In two cases, FGFR3-TACC3 fusions were discovered in patients whose tumors harbored known EGFR mutations (exon 19 deletions) and had been treated with and progressed during therapy with EGFR tyrosine kinase inhibitors (TKIs). We detected two cases of FGFR2-KIAA1598 fusions, which have been previously described in cholangiocarcinoma. 13 We also detected a BCL2 associated athanogene 4 gene (BAG4)-FGFR1 fusion, which has been previously reported in lung SCC. 
Co-occurring Alterations
Co-occurring FGFR amplifications were detected in 10% of cases (four of 52), including three cases with FGFR1 amplification (copy numbers of 7, 8, and 14) and two cases with FGFR3 amplification (copy number of 8 and 10). In four of five cases FGFR amplification cooccurred with an FGFR3-TACC3 fusion. Co-occurring alterations in the known NSCLC driver genes EGFR and MNNG HOS Transforming gene (MET) were observed in 8% of cases (four of 52), all of which were adenocarcinomas. In two of these cases, an EGFR exon 19 deletion and an FGFR3-TACC3 fusion co-occurred in samples known to have been collected after treatment with an EGFR TKI. In the third case, a MET exon 14 splice site mutation co-occurred with an FGFR3-TACC3 fusion in a pretreatment sample. In the fourth case with unknown treatment history, a novel ANO3-FGFR4 fusion cooccurred with EGFR L861Q. KRAS mutations were also detected in an additional 6% of cases (three of 52) (one SCC, one adenocarcinoma, and one NSCLC NOS). Additional co-occurring alterations are shown in Figure 2A .
The most commonly co-altered genes in this series were compared with those from a database of 25,005 FGFR wild-type NSCLC tissue samples (Fig. 2B) . Tumor protein p53 gene (TP53), fibroblast growth factor 3 gene (FGF3), fibroblast growth factor 19 gene (FGF19), fibroblast growth factor 4 gene (FGF4), lysine methyltransferase 2D gene (MLL2 [KMT2D] ), fibroblast growth factor receptor substrate 2 gene (FRS2), tuberous sclerosis 1 gene (TSC1), and Fanconi anemia complementation group A gene (FANCA) were altered in a significantly greater fraction of cases in the FGFR fusion-positive series than in the FGFR wild-type series. Conversely, KRAS, EGFR, and serine/threonine kinase 11 (STK11) were altered in a significantly greater fraction of cases in the FGFR wild-type series.
TMB
The median TMB in our 52 cases with FGFR fusions was 8.4 mutations/Mb (range 0-60). Although the difference was not statistically significant, for FGFR fusionpositive adenocarcinoma cases the median TMB was 5.2 mutations/Mb versus 9.6 mutations/Mb for the FGFR fusion-positive SCC subset (p ¼ 0.087). This is compared with a median of 7.0 mutations/Mb in our entire NSCLC FGFR, fibroblast growth factor receptor; SCC, squamous cell carcinoma; NOS, not otherwise specified; FGFR1, fibroblast growth factor receptor 1 gene; FGFR2, fibroblast growth factor receptor 2 gene; FGFR3, fibroblast growth factor receptor 3 gene; FGFR4, fibroblast growth factor receptor 4 gene; TACC3, transforming acidic coiled-coil containing protein 3 gene; amp, amplification; TMB, tumor mutational burden.
cohort (6.1 mutations/Mb in adenocarcinoma and 8.7 mutations/Mb in SCC).
Clinical Response of Novel Fusion FGFR2-LTZTFL1 to an FGFR TKI
We present the case of a 72-year-old male with metastatic NSCLC that was diagnosed in October 2009. At that time, positron emission tomography had revealed a fludeoxyglucose F 18-avid lesion in the right lower lobe; biopsy subsequently yielded the diagnosis of mucinous adenocarcinoma, lepidic subtype. Initial molecular testing at the time of diagnosis did not reveal any alterations in EGFR or ALK. The patients received various therapies including therapies on clinical trials evaluating erlotinib and bevacizumab, NOTCH inhibitor, and carboplatin and azacitidine. In May 2015, the patient underwent repeat lung biopsy at progression of disease and was found to have adenocarcinoma with mucinous features. This biopsy specimen was sent for CGP and the tumor was found to harbor a FGFR2-LZTFL1 fusion. The patient enrolled on a clinical trial and was treated with an investigational pan-FGFR inhibitor, JNJ-42756493 (erdafitinib); he attained a partial response according to the Response Evaluation Criteria in Solid Tumors, version 1.1, with 60% tumor shrinkage after 2 months of therapy (Fig. 3) . He continued to receive this therapy for a total of 11 months. Further disease progression subsequently developed and the patient died without receiving any further therapy.
Discussion
To the best of our knowledge, our cohort of 26,054 patients with NSCLC is the largest to date to be interrogated specifically for FGFR fusions, which were identified in 0.2% of samples. FGFR fusions were seen more frequently in SCC (0.59%) than in adenocarcinoma (0.12%). Although the incidence in our cohort was lower than that reported in another smaller study (1% for all NSCLC), 23 our results are consistent with reports that that FGFR fusions occur more frequently in lung tumors with squamous cell histologic features. This is of particular interest, as the discovery of targetable driver mutations with therapeutic implications has been largely limited to adenocarcinoma. In this study, we limited analysis to FGFR fusions retaining the kinase domain of FGFR fused to an identifiable fusion partner. Consistent with prior reports, fusions with FGFR as the 5' partner (n ¼ 48) were more common than those with FGFR as the 3' partner (n ¼ 4). Of note, additional cases in our NSCLC data set were observed to have rearrangements or truncations in FGFR intron 17 or exon 18 without an identifiable fusion partner, and these alterations may also be activating. Further, only select introns of the FGFR genes were sequenced, as noted in Table 1 ; therefore, it is possible that additional fusions with noncanonical breakpoints may be underrepresented. In this study 14% of cases were sequenced by using a version 1 of the CGP platform, which did not specifically include intron baiting for FGFRs (although approximately half of intron 17 was effectively baited for FGFR1, FGFR3, and FGFR4 because of overhang from exon baiting). In these samples, FGFR fusions were detected in five of 3531 samples (0.14%) versus in 47 of 22,523 samples (0.21%) tested by using version 2 of the assay, which includes some intron baiting of all four FGFRs including hotspot fusion breakpoints (Table 1 ). The overall difference in FGFR fusion frequency between versions 1 and 2 was not statistically significant (p ¼ 0.53), but FGFR2 fusions in particular may have be underrepresented in samples tested by using version 1.
Of the 52 cases identified herein, three known and 11 novel FGFR fusion partners were identified. Notably, an oligomerization domain, including coiled-coil dimerization domains similar to that seen in echinoderm microtubule associated protein like 4 gene (EML4), which is the most common ALK partner gene, was present in eight of 10 unique 3' fusion partners. 24 In the four cases with FGFR as the 3' gene, the 5' fusion partners included the BCL2 associated athanogene 4 antiapoptotic protein with retention of the BAG binding domain, the anoctamin 3 transmembrane protein, and nuclear receptor binding SET domain protein 1 and nuclear receptor binding SET domain protein 2 (WHSC1), which are SET domaincontaining proteins with zinc finger domains.
Tumors positive for FGFR3 fusions have been shown to be sensitive to FGFR inhibition. 25 We have presented the case of a patient with lung adenocarcinoma harboring a novel FGFR2-LZTFL1 fusion who had a prolonged response to treatment with an FGFR inhibitor. This suggests that the FGFR2 fusion in this case was a driver alteration and conveyed sensitivity to FGFR inhibition. Furthermore, FGFR fusions may confer sensitivity to FGFR TKIs, possibly irrespective of the fusion partner, and this should be studied further.
In our cohort, we also identified two patients who had FGFR3-TACC3 fusions in their tumor tissue obtained after treatment with EGFR TKIs for a primary EGFRmutated NSCLC. In one case, comprehensive genomic testing on the tumor before initiation of an EGFR TKI was performed and no FGFR3 fusion was detected, confirming that the fusion was acquired after treatment. In the other case, only EGFR testing was performed before treatment, so we could not confirm that the fusion was not present initially. However, both of these cases, as well as similar cases in which the FGFR3 fusion was detected in tissue or circulating tumor DNA after administration of an EGFR TKI but was not found in the pretreatment sample, have been described previously. 26 This adds to emerging data that support FGFR alterations not only as a primary driver mutation but also as a potential mechanism of resistance to other targeted agents. Terai et al. developed human NSCLC lines resistant to the EGFR TKI gefitinib and showed (after confirming the absence of the T790M mutation) that there was significantly increased expression of FGFR1 compared with that in the parent nonresistant cells. 27 The addition of an FGFR inhibitor restored the sensitivity of these cells to gefitinib. However, in a phase I study (NCT0151969), the combination of an EGFR TKI (erlotinib) with dovitinib (a multireceptor TKI with activity against FGFR1 and FGFR3) led to intolerable toxicity. 28 Therefore, it may be more feasible to consider combining EGFR inhibitors with more selective FGFR inhibitors currently in clinical development. Whether serial administration of these agents (i.e., an EGFR TKI followed by, or alternated with, a FGFR inhibitor when a FGFR alteration is detected) may be effective is also unknown. FGFR alterations as mechanisms of resistance should continue to be studied to further inform appropriate clinical care for these patients.
Aside from the two cases with co-occurring primary EGFR exon 19 deletion mutations, only two of the 50 remaining FGFR fusion-positive cases in our data set had a co-occurring known targetable driver alteration (MET exon 14 splice and EGFR L861Q) included in the NSCLC National Comprehensive Cancer Network guidelines (version 1.2018). In the case with MET exon 14 splice and FGFR3-TACC3, the patient had not received any prior targeted therapy, and in the case with EGFR L861Q and ANO3-FGFR4 the treatment history is unknown. The lack of other known drivers in the remaining cases suggests that the fusion is likely to be the driving alteration. Further, in adenocarcinoma cases harboring FGFR fusions in the data set, the TMB was relatively low (median 5.2 mutations/Mb), which is consistent with that seen in tumors harboring other targetable driver alterations such as ALK fusions. 29 This is also consistent with the median TMB being lower in patients with lung adenocarcinomas overall (median TMB 6.1 mutations/Mb in our data set), who tend to have a higher frequency of known driver alterations and a lower incidence of smoking history than do patients with lung SCCs (median TMB 8.7 mutations/Mb in our data set).
Compared to a large database of NSCLC samples matched for disease type, many of the frequently altered genes were similar to those seen in this series of FGFR fusion-positive samples; however, there were notable exceptions. As expected, alterations in known NSCLC drivers (KRAS and EGFR) were significantly less common in this series than in FGFR wild-type NSCLC. STK11 alterations were also significantly less common in this series. Notably, amplification of genes encoding the FGFR ligands FGF3, FGF4, and FGF19 and FRS2 was significantly more common in FGFR fusion-positive cases than in FGFR wild-type NSCLC.
In conclusion, FGFR3-TACC3 fusions, as well as diverse FGFR1, FGFR2, FGFR3, and FGFR4 fusions retaining the FGFR kinase domain likely representing targetable drivers, were found in 0.2% of NSCLCs in this study. Unlike other classic driver fusions in NSCLC, which most commonly occur in adenocarcinomas, 40% of FGFR fusion-positive cases in our data set were SCCs. CGP to detect these alterations as part of routine clinical care, as well as continued clinical development of effective FGFR inhibitors in NSCLC, is warranted. 
